Check out our Current Issue!! . Figure from "Telomerase Immunocytochemistry in Lymphocytes From Chronic Lymphocytic Leukemia” by Sučić, et al. 🔗 Read the full article here:

Immune Checkpoint Molecule Expression, 9p24.1 Gene Alterations, and Tumor Microenvironment of Primary Central Nervous System Lymphomas and Their Clinical Relevance

Tissue Factor Pathway Inhibitor-2 Expression in Uterine Cervical Clear Cell Carcinoma: A Potential Biomarker for Clinical Diagnosis

RT @IHC_guy: We’re one day away from David Dabbs’ @ISIMMweb webinar highlighting the HER2 CASI study—our final webinar of the academic year….

Just published! Check out this latest article by @indulkarshreeya @vishalrao1980. 🔬 Molecular subtyping of bladder cancer is vital—but often out of reach.🧪 IHC markers GATA3, KRT20, KRT14, KRT5 used to stratify UCs.⚠️ Dual-negative had poorest survival (25%), luminal best (80%)

Deciphering the Molecular Landscape of Urothelial Carcinoma: Immunohistochemistry-based Subtyping Using 4 Easily Available Antibodies for Cost-effective Stratification

The Expression and Clinical Features of 8 Immunohistochemistry Markers in Adrenal Cortical Adenomas and Pheochromocytomas

Just published! Check out this latest article! .🔵 PD-L1 expression showed high concordance between cores and full slides. 🔵 CD8+ T cell and CD68+ macrophage densities varied; cores underrepresented immune infiltrates. @fabiotavora #IHCpath #lungcancer

Immune Profiling of Incidental NSCLC Patients: Comparison Between Tumor Sections and TMA Cores

🚨 In distal bile duct cancer: .🔹 LATS1/2 expressed in 29.9% ➡️ linked to better prognosis.🔹 YAP (52.2%) & TEAD4 (19.4%) ➡️ tied to advanced stage & worse survival.🔍 Combined LATS1/2⁺ + YAP/TEAD4ˡᵒʷ ➡️ independent favorable prognostic marker.#HippoPathway #LATS1 #YAP #TEAD4

RT @IHC_guy: I'm delighted to share that the recording of @DrCristinaMagi's @ISIMMweb webinar has been added to our website: .

Expression of Hippo Pathway Molecules in Distal Bile Duct Cancer

Just published! Check out this latest article by @RezaTaha_ @fouad_boulos 👉🏻 HER2 amplification is rare (1.7%) in low-grade, tubule-forming breast cancers with 2+ HER2 IHC; findings suggest ISH may be unnecessary in this subset #breastpath #IHCpath @washu_pathology.

CD140b (PDGFRB) Expression in Atypical Fibroxanthoma/Pleomorphic Dermal Sarcoma and its Cutaneous Neoplastic Mimics

The Value of Routine Reflex In Situ Hybridization Testing in Low-grade Tubule-forming Invasive Breast Cancers With Equivocal HER2 Immunohistochemistry - A Reappraisal of the ASCO/CAP Guidelines

Evaluation of Diagnostic Accuracy of Immunohistochemical Markers of SATB2 and Villin in Differential Diagnosis of Ovarian and Gastrointestinal Mucinous Carcinoma

🧬 Immunohistochemistry in Thymomas.▪️ Bcl-2 and D2-40 positivity varies across thymoma subtypes.▪️ E-cadherin is reduced in invasive tumors.▪️ β-catenin shows subtype-specific expression patterns.📊 66 resected cases analyzed. @byrk_bsr #pathtwitter #pathology #thymoma

Differential Expression Patterns of Bcl-2, D2-40, β-Catenin, and E-Cadherin in Thymomas: Correlation With Clinical Stages and Subtypes

Telomerase Immunocytochemistry in Lymphocytes From Chronic Lymphocytic Leukemia . ✨hTERT shows stronger nuclear staining in B-CLL cells vs. normal; linked to poor B-CLL prognosis #IHCpath #hemepath @katcollmd @IHC_guy .🔗

Correlation of MammaPrint to Histopathologic Variables and Comparison to Magee Equations in Adjuvant and Neoadjuvant Cohorts of Estrogen-Receptor Positive HER2-Negative Breast Carcinoma